Lange W, Brugger W, Rosenthal F M, Kanz L, Lindemann A
Albert-Ludwigs University Medical Center, Department of Hematology and Oncology, Freiburg, Germany.
Int J Cell Cloning. 1991 Jul;9(4):252-73. doi: 10.1002/stem.5530090403.
The availability of sufficient quantities of recombinant human cytokines and promising preclinical data have led to their introduction into clinical trials. Cytokines have potential as new therapeutic agents in a variety of hematological disorders as well as in solid tumors. Only a few of the still increasing number of these glycoprotein hormones have been studied in humans so far, either as single agents or in combination with chemotherapy and other cytokines. Their clinical effects, beneficial role in supportive care, and use in the treatment of certain cancer patients are reviewed.
充足数量的重组人细胞因子的可获得性以及有前景的临床前数据促使它们被引入临床试验。细胞因子在多种血液系统疾病以及实体瘤中具有作为新型治疗药物的潜力。到目前为止，在这些数量仍在增加的糖蛋白激素中，只有少数几种在人体中进行了研究，无论是作为单一药物还是与化疗及其他细胞因子联合使用。本文对它们的临床效果、在支持性治疗中的有益作用以及在某些癌症患者治疗中的应用进行了综述。
